AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 FEB 11 - (NewsRx.com & NewsRx.net) -- The Herpevac Trial for Women, conducted by the U.S. National Institute of Allergy and Infectious Diseases, GlaxoSmithKline Biologicals, and numerous research sites, is seeking healthy women ages 18-30 to volunteer for the final clinical trial phase of the new vaccine.
Approximately one in four women in the United States has genital herpes. Symptoms are often subtle; most people don't know they have the disease. The herpesvirus causes cold sores and genital herpes. Although thousands or millions of Americans have the disease, 90% are unaware of this common infection. Even people who do not have visible symptoms can spread the disease. The disease burden is estimated at between $300 million to $1 billion per year in the U.S. alone. There is no treatment that can eliminate the virus.
The Herpevac Trial for Women is investigating a promising vaccine to protect women against genital herpes. This vaccine does not contain live virus and cannot cause herpes infection. It has passed preliminary testing for safety and effectiveness and is now in its final phase of clinical trials.
For this study, more than 20 sites involved in the trial are seeking to enroll approximately 7,550 ...